Tamoxifen mediated human endometrial carcinogenesis may not involve estrogenic pathways: A preliminary note

Anticancer Research

Volumn 16, Issue 5 A, 1996, Pages 2993-2996

  Kuwashima, Yoshio ^a   Kurosumi, Masafumi ^a   Kobayashi, Yasuhito ^a   Tanuma, Junichi ^a,b   Suemasu, Kimito ^a   Higashi, Yasuhiro ^a   Kasamatsu, Takahiro ^a   Shiromizu, Kenji ^a   Matsuzawa, Masumi ^a   Kishi, Kiyozo ^a  

^a SAITAMA CANCER CENTER   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Breast cancer; Endometrial carcinoma; Estrogen receptor; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CARCINOGENESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA ADDUCT; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 10544246485     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Cancer Research Campaigll Breast Cancer Trials Group: The effect of adjuvant tamoxifen the latest results from the Cancer Research Campaign Adjuvant Breast Trial. Eur J Cancer 28A: 904-907, 1992.
2. Pasqualini JR, Sumida C and Giambiagi N: Pharmacodynamic and biological effects of anti-estrogens in dfflerent models. J Steroid Biochem 31: 613-643, 1988.
3. Hirsimaki P, Hirsimaki Y, Nieminen L and Payne, BJ: Tamoxifen induceshepatocellular carcinoma in rat liver: a 1-year study with 2 antiestrogens. Arch Toxicol 67: 49-54, 1993.
4. Greaves P, Goonetilleke R, Nunn G, Topham J and Orton T: Two-year carcinogenicity study of tamoxifen in Alderby Park Wisterderived rats. Cancer Res 53: 3919-3924, 1993.
5. Williams GM, Iatropoulos MJ, Djordjevic MV and Kaltenberg OP: The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14: 315-317, 1993.
6. Carthew P, Martin EA, White INH, De Matteis F, Edwards RE, Dorman BM, Heydon RT and Smith LL: Tamoxifen induces short-term cumulative DNA damage and liver tumors in rat: promortion by phenobarbital. Cancer Res 55: 544-547, 1995.
7. 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumor formation. Carcinogenesis 16: 1299-1304, 1995.
8. Jordan VC: Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol 35: 195-211, 1995.
9. Sismondi P, Biglia N, Giai M, Sego L and Campagnoli C: Metabolic effects of tamoxifen in postmenopause. Anticancer Res 14: 2237-2244, 1994.
10. Yager JD, Roebuck BD, Paluszcyk TL and Memoli VA: Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase positive foci in female rats. Carcinogenesis 7: 2007-2014, 1986.
11. van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney LALM, Gimbrere CHF, Otter R, Schoutcn LJ, Damhuis RAM, Bontenbal M, Diepenhorst FW, van den Belt-Dusebout AW and van Tinteren H: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343: 448-452, 1994.
12. Friedl A and Jordan VC: What do we know and what don't we know about tamoxifen in the human uterua Breast Cancer Res Treat 31: 27-39, 1994.
13. Lanza A, Alba E, Re A, Tessarolo M, Leo L, Bellino R, Lauricella A and Wierdis T: Endometrial carcinoma in breast cancer patients treated with tamoxifen. two case report and review of the literature. Eur J Gynaecol Oncol 15: 455-459, 1994.
14. Barakat RR, Wong G, Curtin JP, Vlamis V and Hoskins WJ: Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 55: 164-168, 1994.
15. Ismail SM: Pathology of endometrium treated with tamoxifen. J Clin Pathol 47: 827-833, 1994.
16. Hammond CB, Jelovsek FR, Lee KL, Creasman WT and Parker RT: Effects of long-term estrogen replacement therapy. II neoplasia. Am J Obstet Gynecol 133: 537-547, 1979.
17. McGonigle KF, Karlan BY, Barbuto DA, Leuchter RS, Lagassc LD and Judd HL: Development of endometrial cancer in women on estrogen and progesterone hormone replacement therapy. Gynecol Oncol 55: 126-132, 1994.
18. Magripbs U, Naftolin F, Schwartz PE and Carcangiu ML: High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11: 485-490, 1993.
19. Kader N, Malfetano JH and Homesley HD: Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. Gynecol Oncol 50: 281-286, 1993.
20. Kerner H, Sabo E, Friedman M, Beck D, Samare O and Lichtig C: An immunohistochemical study of estrogen and progesterone receptors in adenocarcinoma of the endometrium and in adjacent mucosa. Int J Gynecol Cancer 5: 275-281, 1995.
21. Hsu SM, Raine L and Fanger H: Use of avidin-biotin-peroxydase complex(ABC) in immunoperoxidase technique: a comparison between ABC and unlabeled antibody(PAP) procedures. J Histochem Cytochem 29: 577-580, 1981.
22. Hemminki K, Widlak P and Hou SM: DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis 16: 1661-1664, 1995.
23. Dallenbach-Hellweg G and Hahn U: Mucinous and clear cell adenocarcinomas of the endometrium in patients receiving antiestrogens(tamoxifen) and gestagens. Int J Gynecol Pathol 14: 7-15, 1995.
24. Silva EG, Tornos CS and Follen-Mitchell M: Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol 13: 248-258, 1994.